Black Diamond Therapeutics (BDTX) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Conservation Emission Environment Environmental Environmental Protection Extreme Weather Forest Intensity Lifecycle Materials Nature Offset Package Packaging Pandemic Raw Materials Recycling Resiliency Toxic Waste Water Access African American Asian Attrition Benefits Black California Consumer Privacy Act Collective Bargaining Community Culture Customer Cyber Cyber Security Cybersecurity Data Privacy Data Security Death Demographic Disability Diversity Diversity and Inclusion Drug Pricing Employee Engagement Ethnic Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Minority Pay for Performance Philanthropic Privacy Product Quality Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workers Workforce Assessment Assurance Attorneys General Audit Bonus Bribe Bribery Classified Commitment Conflict of Interest Corporate Governance Corporate Purpose Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovate Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Pledging Proxy Contest Purpose Quality Standard R&D Recoup Reputation Reputational Reputational Risk Research and Development Responsibility Responsible Special Meeting Strategy Targets Tax Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 16, 2023, Black Diamond Therapeutics, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy statement (the “Proxy Statement”) filed on April 4, 2023 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. As of March 20, 2023, the record date for the Annual Meeting, the number of shares of the Company’s common stock, $0.0001 par value per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting was 36,504,836. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 31,052,957 thus establishing a quorum for the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common Stock represented in person at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company’s stockholders at the Annual Meeting.

At the Annual Meeting, the Company’s stockholders were asked to vote on the following matters, which are described in detail in the Proxy Statement: (i) to elect three Class III director nominees to the Company’s Board of Directors (the “Board”), each to serve until the Company’s 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal (“Proposal No. 1”) and (ii) to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (“Proposal No. 2”).

The voting results reported below are final.

Proposal No. 1

David M. Epstein, Wendy L. Dixon and Kapil Dhingra were duly elected to the Board as Class III directors. The results of the election were as follows:

CLASS II DIRECTOR NOMINEE	FOR		WITHHELD		BROKER NON- VOTES
David M. Epstein		26,357,348		84,077		4,611,532
Wendy L. Dixon		19,131,310		7,310,115		4,611,532
Kapil Dhingra		20,012,773		6,428,652		4,611,532

Proposal No. 2

The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The results of the ratification were as follows:

FOR		AGAINST			ABSTAIN
31,012,770			22,331			17,856

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.